Kymera Therapeutics, Inc. 8-K Filing
Ticker: KYMR · Form: 8-K · Filed: Dec 10, 2025 · CIK: 1815442
| Field | Detail |
|---|---|
| Company | Kymera Therapeutics, Inc. (KYMR) |
| Form Type | 8-K |
| Filed Date | Dec 10, 2025 |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $86.00, $656.1 million |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Kymera Therapeutics, Inc. (ticker: KYMR) to the SEC on Dec 10, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.0001 (nge on which registered Common Stock, $0.0001 par value per share KYMR The Nasdaq); $86.00 (on Stock"), at a price to the public of $86.00 per share (the "Offering"). Under the t); $656.1 million (ffering expenses, will be approximately $656.1 million. The Company intends to use the net pro).
How long is this filing?
Kymera Therapeutics, Inc.'s 8-K filing is 4 pages with approximately 1,258 words. Estimated reading time is 5 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 1,258 words · 5 min read · ~4 pages · Grade level 11.8 · Accepted 2025-12-10 17:17:25
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share KYMR The Nasdaq
- $86.00 — on Stock"), at a price to the public of $86.00 per share (the "Offering"). Under the t
- $656.1 million — ffering expenses, will be approximately $656.1 million. The Company intends to use the net pro
Filing Documents
- d89982d8k.htm (8-K) — 33KB
- d89982dex11.htm (EX-1.1) — 203KB
- d89982dex51.htm (EX-5.1) — 6KB
- d89982dex991.htm (EX-99.1) — 10KB
- d89982dex992.htm (EX-99.2) — 11KB
- g89982dsp_48.jpg (GRAPHIC) — 7KB
- 0001193125-25-314422.txt ( ) — 446KB
- kymr-20251208.xsd (EX-101.SCH) — 3KB
- kymr-20251208_lab.xml (EX-101.LAB) — 18KB
- kymr-20251208_pre.xml (EX-101.PRE) — 11KB
- d89982d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description 1.1 Underwriting Agreement, dated December 9, 2025, by and among Kymera Therapeutics, Inc. and Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, Jefferies LLC, Stifel, Nicolaus & Company, Incorporated, Guggenheim Securities, LLC and Wells Fargo Securities, LLC. 5.1 Opinion of Goodwin Procter LLP 23.1 Consent of Goodwin Procter LLP (contained in Exhibit 5.1) 99.1 Launch Press Release dated December 8, 2025, furnished herewith. 99.2 Pricing Press Release dated December 9, 2025, furnished herewith. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Kymera Therapeutics, Inc. Date: December 10, 2025 By: /s/ Nello Mainolfi Nello Mainolfi, Ph. D. President and Chief Executive Officer